Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre,... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Oncology Pubmed

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

The Lancet Oncology , Volume 20 (5): 13 – Jun 15, 2020

Loading next page...
 
/lp/pubmed/niraparib-monotherapy-for-late-line-treatment-of-ovarian-cancer-quadra-EOBWuZr8Rr

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
ISSN
1470-2045
eISSN
1474-5488
DOI
10.1016/S1470-2045(19)30029-4
pmid
30948273

Abstract

Journal

The Lancet OncologyPubmed

Published: Jun 15, 2020

There are no references for this article.